NASDAQ
4.22USD
+0.04 (+0.96%)
We have scored 5 news catalysts on Arbutus Biopharma Corp (ABUS) over the past 12 months. The biggest single-day move next to one of them came Aug 21, 2026, when ABUS closed +9.2%: “Arbutus Announces Intent to Repurchase Up to US$230 Million of its Common Shares Through Modified “Dutch Auction” Tender Offer”. Coverage across the window leans positive (average ticker sentiment +0.76). Most of the impact sits in short squeeze potential and eps growth rate.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
833.6M
P/E
—
EPS
—
Beta
0.62
52W range
3.5-5.45
Day range
4.13–4.27
Open
4.17
Prev close
4.18
Volume
3.1M
Avg volume
4.1M
Dividend
0.00
IPO
2007-07-26
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Arbutus Biopharma Corp — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for ABUS: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients’ HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.
